Opthea Limited (OPT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 South Yarra, VIC, 호주. 현재 CEO는 Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,.
OPT 을(를) 보유 IPO 날짜 2020-10-16, 33 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $4.24B.
Opthea Limited is a clinical-stage biopharmaceutical company based in South Yarra, Australia, focused on developing therapies for eye diseases. The company's pipeline is built on intellectual property targeting VEGF-C, VEGF-D, and VEGF Receptor-3 to address conditions involving abnormal blood and lymphatic vessel growth and vascular leakage. Its lead candidate, OPT-302, is a soluble VEGFR-3 inhibitor in clinical development for wet age-related macular degeneration and diabetic macular edema, designed to work alongside VEGF-A inhibitors for improved efficacy in retinal diseases.
